Key result
Postoperative administration of levosimendan decreased the incidence of kidney failure at ICU discharge to 0% compared to 40% with beta-agonists in cardiac surgery patients with low cardiac output syndrome.
Why the study?
Levosimendan treats low cardiac output syndrome after cardiac surgery and seems to protect renal function, but its effects on postoperative kidney failure compared to beta-agonists needed assessment.
Does levosimendan reduce postoperative kidney failure in cardiac surgery patients with low cardiac output syndrome compared to beta-agonists?
Observational (n=100)
No
Does levosimendan reduce postoperative kidney failure in cardiac surgery patients with low cardiac output syndrome compared to beta-agonists?
In cardiac surgery patients with low cardiac output syndrome, levosimendan administration was associated with a lower incidence of postoperative kidney failure compared to standard beta-agonist therapy.
Answers are grounded in this paper and cite their sources.
May support levosimendan over beta-agonists to avert kidney failure in low-output cardiac surgery; leaves open need for RCT confirmation.
BACKGROUND: Some studies have been performed to assess the effects of levosimendan on cardiac function when administered to cardiac surgery patients with low cardiac output syndrome (LCOS) in the immediate postoperative period. Levosimendan is an inotropic agent for the treatment of low cardiac output syndrome that seems to have a protective effect on renal function. METHODS: It is a quasi-experimental study. A total of 100 patients with LCOS received either beta-agonists or levosimendan. We assessed the incidence of postoperative kidney failure in cardiac surgery patients. In patients who had kidney failure at diagnosis of LCOS, we examined whether differences existed in the evolution of kidney failure based on the treatment administered for LCOS. The parameters measured included haemodynamics, oxygen supply, and renal function as assessed by the AKI scale. ANOVA, Student's t-test and Wilcoxon or Friedman tests were used. RESULTS: Up to 30% of cardiac surgery patients had kidney failure at diagnosis of LCOS. Kidney failure at discharge from the ICU was more frequent in patients who received beta-agonist drugs as compared to those who received levosimendan (p < 0.05). CONCLUSION: The incidence of kidney failure decreased with the postoperative administration of levosimendan to cardiac surgery patients with LCOS, as compared to beta-agonists. TRIAL REGISTRATION: Current Controlled Trials ISRCTN 46058317. Date of registration: 7/10/2019. Retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Orriach et al. (2019) conducted an observational in Low cardiac output syndrome (LCOS) following heart surgery (n=100). Levosimendan vs. Beta-agonists (adrenaline or dobutamine) was evaluated on Incidence of kidney failure at ICU discharge among patients with renal dysfunction at LCOS diagnosis (p=<0.05). Postoperative administration of levosimendan decreased the incidence of kidney failure at ICU discharge to 0% compared to 40% with beta-agonists in cardiac surgery patients with low cardiac output syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: